Sugi Predict

Sugi Predict / Compounds / SCHEMBL1999164

SCHEMBL1999164

SCHEMBL1999164

COCCN1CCC(CO)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 2/20 0.47
▸ LTA4H P09960 2/20 0.38
▸ ARG1 P05089 1/20 0.38
▸ ARG2 P78540 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ KDM2B Q8NHM5 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KDM1A O60341 1/20 0.35
▸ PDCD1 Q15116 2/20 0.34
▸ CD274 Q9NZQ7 2/20 0.34
▸ ACHE P22303 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ ROCK2 O75116 1/20 0.34
▸ ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4386158 0.89 MAPT (0.46) GBA1ALDH1A1MAPTMEN1KMT2A
SCHEMBL315893 0.89 LTA4H (0.47) GBA1LTA4HALDH1A1HSD11B1SMN1; SMN2
SCHEMBL23205833 0.85 ALDH1A1 (0.39) GBA1LTA4HALDH1A1MAPTHSD11B1
SCHEMBL12458880 0.83 GBA1 (0.38) GBA1LTA4HALDH1A1HSD11B1MEN1
SCHEMBL18082565 0.83 GBA1 (0.38) GBA1LTA4HALDH1A1HSD11B1MEN1
SCHEMBL11972716 0.81 NCF1 (0.45) GBA1LTA4HALDH1A1HSD11B1MEN1
SCHEMBL3234901 0.80 MAPT (0.42) GBA1MAPTMEN1KMT2AKDM2B
SCHEMBL3234907 0.80 MAPT (0.42) GBA1MAPTMEN1KMT2AKDM2B
SCHEMBL12374980 0.80 GBA1 (0.36) GBA1LTA4HALDH1A1HSD11B1MEN1
SCHEMBL19637813 0.80 GBA2 (0.43) GBA1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
CN-109843856-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2023-05-02 — — CN disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
US-11267812-B2 KRAS G12C inhibitors Mirati Therapeutics, Inc. (US) 2022-03-08 — — US disclosed
EP-3458445-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2021-02-17 — — EP disclosed
CN-111989321-A KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2020-11-24 — — CN disclosed
US-20200262837-A1 KRAS G12C INHIBITORS ARRAY BIOPHARMA INC. 2020-08-20 — — US disclosed
US-10689377-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-06-23 — — US disclosed
US-9428452-B2 Compounds GLAXO GROUP LIMITED (GB) 2016-08-30 — — US disclosed
EP-2886545-B1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2016-06-29 — — EP disclosed
WO-2015097123-A1 NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2015-07-02 — — WO disclosed
US-20150175623-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2015-06-25 — — US disclosed
EP-2886545-A1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2015-06-24 — — EP disclosed
CN-104725397-A Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB 2015-06-24 — — CN disclosed
US-20150080369-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2015-03-19 — — US disclosed
US-20150080369-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2015-03-19 — — US disclosed
WO-2013160418-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-10-31 — — WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080369-A1 NOVEL COMPOUNDS RORC, RORB, RORA GBA1 2234/4885LTA4H 664/4885ARG1 1120/4885
US-20200262837-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS GBA1 2271/4885LTA4H 3802/4885ARG1 4028/4885
US-11267812-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS GBA1 2271/4885LTA4H 3802/4885ARG1 4028/4885
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO GBA1 2394/4885LTA4H 438/4885ARG1 1348/4885
US-10689377-B2 KRas G12C inhibitors KRAS, NRAS, HRAS GBA1 2271/4885LTA4H 3802/4885ARG1 4028/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS GBA1 2271/4885LTA4H 3802/4885ARG1 4028/4885
US-20150175623-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 GBA1 3913/4885LTA4H 1939/4885ARG1 1066/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS GBA1 2271/4885LTA4H 3802/4885ARG1 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.